Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy
Carmine De Angelis(Baylor College of Medicine), Rachel Schiff(Baylor College of Medicine), Yi Zheng(Cornell University), Carolina Gutiérrez(Baylor College of Medicine), Antonio C. Wolff(Johns Hopkins University), C. Kent Osborne(Baylor College of Medicine), Maria Letizia Cataldo(Baylor College of Medicine), Kristin Roman(Akoya Biosciences (United States)), Vidyalakshmi Sethunath(Dana-Farber Cancer Institute), Sufeng Mao(Baylor College of Medicine), Britta Weigelt(Memorial Sloan Kettering Cancer Center), Meghana V. Trivedi(University of Houston), Chandandeep Nagi(Icahn School of Medicine at Mount Sinai), Jamunarani Veeraraghavan(Baylor College of Medicine), Mothaffar F. Rimawi(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), Jorge S. Reis‐Filho(Institute of Cancer Research), Anna Tsimelzon(Pancreatic Cancer Action Network), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Anne C. Pavlick(Baylor College of Medicine), Aleix Prat(Breast Cancer Research Foundation), Tao Wang(Pfizer (United States)), Linying Liu(Akoya Biosciences (United States)), Chichung Wang(Akoya Biosciences (United States)), Cliff C. Hoyt(Akoya Biosciences (United States))
Cited by 87
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.2k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k